Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRF6021 in Parkinson's Disease with Cognitive Impairment
NCT03713957Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Nov 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) and cognitive impairment comparing GRF6021 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-emergent Adverse Events and Serious Adverse Events at 24 months. Started Nov 2018; status: completed.
02
Drugs
GRF6021
03
Conditions
Parkinson's disease (PD)cognitive impairment
Beyond the preview
Go deeper on NCT03713957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713957.